Author: Ravi Shankar

MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the signing of an exclusive distribution agreement with Kyowa Kirin International (“KKI”), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151) (“Kyowa Kirin”), a Japan-based global specialty pharmaceutical company, for mogamulizumab (sold as POTELIGEO® in the United States and Europe) across certain Latin American countries. Under the terms of this agreement Knight will be responsible for obtaining regulatory approval and commercializing mogamulizumab in Brazil, Mexico, Colombia and Argentina.

Mogamulizumab is a humanized monoclonal antibody (mAb) targeting chemokine receptor 4 (CCR4), a receptor expressed on malignant T cells. POTELIGEO® is approved in the United States and Europe for treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), after at least one prior systemic therapy, the two most common subtypes of cutaneous T-cell lymphoma (CTCL).^1,2,3

CTCL is a rare form of non-Hodgkin lymphoma that can affect the skin, blood, lymph nodes and internal organs.^4,5 CTCL often presents with persistent, inflamed skin lesions that can resemble benign dermatologic conditions, leading to delayed diagnosis and treatment. Patients frequently endure painful, itchy, and disfiguring skin symptoms that fluctuate unpredictably, contributing to physical discomfort, emotional distress, and can lead to a reduced life expectancy.⁶ Epidemiological data for CTCL in Latin America is limited, but is believed to be in line with the United States where the reported annual incidences of MF and SS are 5.42 per million and 0.21 per million, respectively.⁷ Together MF and SS represent approximately 65% of all cases of CTCL.⁵

“We are thrilled to add Kyowa Kirin, a Japan-based global specialty pharmaceutical company, as a new Knight partner. POTELIGEO® represents an innovative advancement in the treatment of rare cancers, specifically mycosis fungoides and Sézary syndrome. Its addition to our hemato-oncology portfolio addresses a significant unmet medical need and will provide patients across our key Latin American markets with access to a much-needed new therapeutic option,” said Samira Sakhia, President and CEO of Knight Therapeutics Inc.

Céline Rhême, Cluster General Manager, Emerging Growth Markets, Kyowa Kirin International, commented: “CTCL is more common in this region than many realise, and further work is needed to identify unmet needs and therefore drive improvements in patient outcomes.⁸ We have an opportunity, and a responsibility, to change that. Through our proud partnership with Knight Therapeutics, we can help to increase patient access in Latin America, as part of our ongoing and relentless commitment to bring life-changing value and make people smile.”

About Mogamulizumab

Mogamulizumab is a first-in-class humanized mAb directed against CCR4, a protein expressed on cancerous cells seen in both MF and SS. ^9,10,11 Once mogamulizumab binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells.¹²

The approval of POTELIGEO® (mogamulizumab) is supported by the MAVORIC (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) study, which is the largest randomized trial in MF and SS and the first to compare systemic therapies using progression-free survival (PFS) as a primary endpoint. MAVORIC was a Phase 3 open-label, multi-center, randomized study of mogamulizumab versus vorinostat in patients with MF and SS who have failed at least one prior systemic treatment. The study randomized a total of 372 patients to mogamulizumab or vorinostat. The results showed that mogamulizumab demonstrated significantly superior PFS at a median of 7.7 months [95% CI: 5.7, 10.3] compared to 3.1 months with vorinostat [95% CI: 2.9, 4.1], [hazard ratio 0.53: 95% CI: 0.41, 0.69; p<0.001]. The confirmed overall response rate for mogamulizumab and vorinostat was 28% and 5%, respectively (risk ratio [RR] 23.1, 95% CI 12.8–33.1; p<0.001).¹³ The most common side effects associated with mogamulizumab vs vorinostat included rash (36% vs 22%), infusion related reactions (33% vs <1%), upper respiratory tract infections (22% vs 16%), musculoskeletal pain (22% vs 17%), fever (18% vs 6%), and mucositis (14% vs 6%), respectively.¹⁴

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s website at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. Kyowa Kirin, Inc. Poteligeo (mogamulizumab-kpkc) injection, for intravenous use [prescribing information]. Bedminster, NJ; 2018. Accessed November 11, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761051s000lbl.pdf
2. European Medicines Agency. Poteligeo: EPAR – Product information. Accessed November 11, 2025. https://www.ema.europa.eu/en/documents/product-information/poteligeo-epar-product-information_en.pdf
3. Martinez XU, Di Raimondo C, Abdulla FR, Zain J, Rosen ST, Querfeld C. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome. Best Pract Res Clin Haematol. 2019;32(3):239-252. doi:10.1016/j.beha.2019.06.004
4. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714. doi:10.1182/blood-2018-11-
5. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722. doi:10.1182/blood-2007-03-
6. Haun PL, Scarisbrick JJ. Fast Facts: Cutaneous T-cell Lymphoma. Karger Medical and Scientific Publishers; 2019. Accessed November 11, 2025. https://books.google.ca/books?id=bdRwEQAAQBAJ
7. Cai ZR, Chen ML, Weinstock MA, Kim YH, Novoa RA, Linos E. Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis. JAMA Oncol. 2022;8(11):1690-1692. doi:10.1001/jamaoncol.2022.
8. Dobos G, Pohrt A, Ram-Wolff C, Lebbé C, Bouaziz JD, Battistella M, Bagot M, de Masson A. Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. Cancers (Basel). 2020 Oct 11;12(10):2921. doi: 10.3390/cancers12102921. PMID: 33050643; PMCID: PMC7600606.
9. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119(6):1405-1410. doi:10.1046/j.1523-1747.2002.19610.
10. Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood. 2002;99(5):1505-1511. doi:10.1182/blood.v99.5.
11. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625-3634.
12. Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171-174. doi:10.1177/
13. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-1204. doi:10.1016/S1470-2045(18)30379-6
14. Kyowa Kirin, Inc. POTELIGEO (mogamulizumab for injection) [product monograph]. Bedminster, NJ: Kyowa Kirin, Inc.; June 20, 2022. Accessed November 12, 2025. https://pdf.hres.ca/dpd_pm/00066376.PDF

CONTACT INFORMATION FOR KNIGHT:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia		Arvind Utchanah
President & Chief Executive Officer		Chief Financial Officer
T: 514.484.4483		T: 514.484.4483
Email: IR@knighttx.com		Email: IR@knighttx.com
Website: www.knighttx.com		Website: www.knighttx.com

This press release was published by a CLEAR® Verified individual.

• Drilling confirms strong continuity of gold mineralisation within the Road Cut Artisanal Shear, while results from northern sections RCZ000 and RCZ-200 identify additional areas for follow-up drilling 
• KDD0191 returned 19.0 m at 1.94 g/t Au, including 9.0 m at 3.29 g/t Au, confirming continuity of mineralisation within the Artisanal Shear
• Drilling on sections RCZ000 and RCZ-200 provides further evidence that the Road Cut gold system continues north into relatively lightly drilled areas
• More than 53,430 m of drilling completed across 260 holes at Kossou, with additional high-grade results returned from the Kadie Zone

QUEBEC CITY, Sept. 29, 2026 (GLOBE NEWSWIRE) — Kobo Resources Inc. (“Kobo” or the “Company”) (TSX.V: KRI) (FWB: Q1Z) is pleased to report diamond drill results from fourteen (14) additional holes completed at its 100%-owned Kossou Gold Project (“Kossou”) in Côte d’Ivoire. Six holes completed at the Road Cut Zone continued to extend and define gold mineralisation across multiple structures, including the Artisanal Shear, Main Road Cut Shear and Contact Zone Fault, with drilling providing further evidence that the mineralised system continues to the north. Eight additional holes tested shear and quartz-vein structures at the Kadie Zone, returning several high-grade gold intercepts.

Diamond Drill Results – Highlights:

Road Cut Zone:

• KDD0191
  • 19.0 metres (“m”) at 1.94 g/t Au from 67.0 m, incl. 14.2 m at 2.44 g/t Au and 9.0 m at 3.29 g/t Au
  • 4.0 m at 2.05 g/t Au from 134.0 m, incl. 1.0 m at 7.17 g/t Au
  • 2.0 m at 2.91 g/t Au from 156.0 m

• KDD0188
  • 7.0 m at 1.28 g/t Au from 245.0 m

• KDD0182
  • 6.0 m at 1.17 g/t Au from 36.0 m

Kadie Zone:

• KDD0192
  • 9.0 m at 2.44 g/t Au from 62.0 m, incl. 2.0 m at 9.78 g/t Au

• KDD0185
  • 2.0 m at 9.26 g/t Au from 213.0 m

Edward Gosselin, CEO and Director of Kobo, commented: “KDD0191 is an important result for our understanding of the core Road Cut system, returning a strong 19.0 m interval while confirming continuity of gold mineralisation within the Artisanal Shear. The hole also intersected additional mineralisation proximal to the Contact Zone Fault, further strengthening our understanding of how these structures contribute to the broader Road Cut gold system.”

He continued: “Separately, drilling farther north on sections RCZ000 and RCZ-200 is providing additional evidence that the Road Cut gold system continues beyond the areas we have drilled more extensively to date. These northern areas remain relatively lightly drilled and give our exploration team clear targets for follow-up as we continue testing the scale of the system.”

Road Cut Zone

KDD0191 Confirms Strong Continuity at the Artisanal Shear at the Road Cut Zone

Drill hole KDD0191 was completed on section RCZ500 (Figure 2) to test the up-dip extension of gold mineralisation associated with the Contact Zone Fault identified in KDD0170, which returned 8.0 m at 2.65 g/t Au from 355.0 m (see press release dated August 6, 2026). KDD0191 returned two intervals proximal to the Contact Zone Fault: 4.0 m at 2.05 g/t Au from 134.0 m, including 1.0 m at 7.17 g/t Au, and 2.0 m at 2.91 g/t Au from 156.0 m. These results confirm the presence of mineralisation associated with shearing and quartz veining along the structure.

KDD0191 was also designed to test continuity of the Artisanal Shear between KDD0012, which returned 11.0 m at 1.71 g/t Au (see press release dated July 11, 2024), and KDD0091, which returned 15.55 m at 2.30 g/t Au, including 8.30 m at 3.43 g/t Au, as previously reported on July 10, 2025. KDD0191 returned 19.0 m at 1.94 g/t Au from 67.0 m, including 14.20 m at 2.44 g/t Au and 9.0 m at 3.29 g/t Au, demonstrating strong continuity of gold mineralisation within the Artisanal Shear on this section. Further drilling is planned across the Main Road Cut Shear, Artisanal Shear and Contact Zone Fault, all of which remain open at depth.

Figure 1: Road Cut Zone Simplified Geology Map with Diamond Drill Hole Collars

Figure 2: Road Cut Zone Simplified Section – RCZ500

Contact Zone Fault Mineralisation Extended Farther North

Drill hole KDD0188 was completed on section RCZ-200 to test for potential mineralisation along the Contact Zone Fault farther north, based on soil geochemistry and surface mapping (Figure 3). Previous drilling in KDD0153 did not successfully intersect the interpreted fault position. Based on updated geological information, KDD0188 was collared within the volcanic package and returned three separate zones of mineralisation, highlighted by 7.0 m at 1.28 g/t Au from 245.0 m directly associated with the Contact Zone Fault.

Two additional lower-grade intervals were intersected in the hanging wall of the Contact Zone Fault, returning 4.85 m at 0.45 g/t Au from 218.0 m and 5.0 m at 0.40 g/t Au from 228.0 m. These results confirm the presence of the mineralised system at depth on this section. Further drilling is planned to test the continuity of mineralisation along the structure in this area and up-dip and down-dip of the current results.

Figure 3: Road Cut Zone Simplified Section – RCZ200

Drilling Confirms Road Cut Shear System Continues North

Two holes were completed on section RCZ000 to test the extension of the shear systems and gold mineralisation north of the main drilling completed to date at the Road Cut Zone (Figure 1). KDD0182 returned the strongest intercept of 6.0 m at 1.17 g/t Au from 36.0 m, interpreted to be associated with the structures parallel to the Road Cut Main shear system. Additional mineralised intervals included 3.0 m at 1.06 g/t Au from 156.0 m and 3.0 m at 1.22 g/t Au from 175.0 m appear to be related to the Road Cut Main shear system.

KDD0186 was completed below KDD0182 and intersected several narrow, weak-to-moderate grade zones, including 2.0 m at 2.17 g/t Au from 164.0 m, 3.0 m at 1.03 g/t Au from 186.0 m and 1.0 m at 1.47 g/t Au from 292.0 m associated with the Contact Zone Fault. These holes provide further evidence that the shear system continues north. The approximately 200 m gap between sections RCZ-200 and RCZ000 remains a target for future drilling.

Kadie Zone

Kadie Drilling Returns Additional High-Grade Gold Intercepts

Eight drill holes were completed at the Kadie Zone to test multiple shear and quartz-vein structures. Significant results include 9.0 m at 2.44 g/t Au from 62.0 m, including 2.0 m at 9.78 g/t Au, in KDD0192 on section KZ275; 2.0 m at 9.26 g/t Au from 213.0 m in KDD0185 on section KZ250; and 2.20 m at 3.91 g/t Au from 62.0 m in KDD0189 on section KZ400.

Most of these intercepts are associated with high-grade quartz-carbonate veins hosted within weakly foliated to unfoliated volcanic rocks. Additional work is required to further define the distribution and continuity of these shear and vein structures. Kobo has completed approximately 4,400 m across 25 drill holes at the Kadie Zone to date.

Figure 4: Kadie Zone Simplified Geology Map with Diamond Drill Hole Collars

Table 1: Summary of Significant Diamond Drill Hole Results

BHID	East	North	Elev.	Az.	Dip	Length		From (m)	To (m)	Int. (m)	Au g/t		Target
KDD0180	228610.55	775626.18	291.64	70	-50		131.3	79	82	3	0.57		Kadie
KDD0181	228518.77	775539.47	304.94	70	-50		273.3	NSR					Kadie
KDD0182	228204.17	776702.14	252.71	70	-50		245.4	36	42	6	1.17		RCZ
								56	59	3	0.61		RCZ
								156	159	3	1.06		RCZ
								168	170	2	0.67		RCZ
								175	178	3	1.22		RCZ
								207	213	6	0.67		RCZ
KDD0183	228601.13	775729.16	303.85	70	-50		140.3	NSR					Kadie
KDD0184	228315.79	776689.99	247.68	70	-50		155.4	33	34	1	1.03	*	RCZ
KDD0185	228528.78	775493.81	313.71	70	-50		284.3	152	153	1	1.26	*	Kadie
								200	201	1	2.26	*	Kadie
								213	215	2	9.26		Kadie
								220	221	1	1.80	*	Kadie
KDD0186	228157.18	776685.04	253.60	70	-50		311.4	103	104	1	1.68	*	RCZ
								107	109	2	0.98		RCZ
								122	123	1	1.19	*	RCZ
								164	166	2	2.17		RCZ
								173	177	4	0.58		RCZ
								186	189	3	1.03		RCZ
								204	208	4	0.38		RCZ
								292	293	1	1.47	*	RCZ
KDD0187	228610.82	775466.45	305.62	70	-50		212.3	39	41	2	0.64		Kadie
								67	68	1	1.22	*	Kadie
								126	127	1	1.01	*	Kadie
								150	152	2	1.03		Kadie
								197	200	3	1.42		Kadie
KDD0188	228043	776855	254.64	70	-50		335.4	69	72	3	1.87		RCZ
								97	98	1	1.02	*	RCZ
								218	222.85	4.85	0.45		RCZ
								228	233	5	0.40		RCZ
								245	252	7	1.28		RCZ
								271	273	2	0.64		RCZ
KDD0189	228684.17	775386.55	323.38	70	-50		221.3	10	12	2	0.56		Kadie
								62	64.2	2.2	3.91		Kadie
								71	72	1	3.49	*	Kadie
								179	180	1	3.28	*	Kadie
KDD0190	228711.20	775343.14	331.64	70	-50		215.3	100	105	5	1.99		Kadie
								100	101	1	8.34	*	Kadie
								135	136	1	2.81	*	Kadie
KDD0191	228534.21	776288.83	218.46	70	-60		179.4	67	86	19	1.94		RCZ
								69	83.2	14.2	2.44		RCZ
								69	78	9	3.29		RCZ
								134	138	4	2.05		RCZ
								137	138	1	7.17	*	RCZ
								156	158	2	2.91		RCZ
KDD0192	228356.80	775400.50	348.48	70	-50		263.3	7	9	2	0.58		Kadie
								41	49	8	0.46		Kadie
								55	57	2	2.44		Kadie
								62	71	9	2.44		Kadie
								62	64	2	9.78		Kadie
								206	208	2	1.23		Kadie
KDD0193	228251.83	776400.53	290.26	70	-50		383.4	132	136	4	0.71		RCZ
								173	177	4	0.76		RCZ
								286.9	288.9	2	1.38		RCZ
								348	350.2	2.2	0.66		RCZ
Notes: Cut-off grade of 0.30 g/t Au over a minimum interval of 2.0 m. Intervals are reported with no more than 3.0 m of internal dilution grading less than 0.30 g/t Au, except where indicated with an asterisk (*).

An accurate dip and strike and controls of mineralisation are unconfirmed and mineralised zones are reported as downhole lengths. Drill holes are planned to intersect mineralised zones perpendicular to interpreted targets. All intercepts reported are downhole distances, true widths are unknown.

Sampling, QA/QC, and Analytical Procedures

Drill core was logged and sampled by Kobo personnel at site. Drill cores were sawn in half, with one half remaining in the core box and the other half secured into new plastic sample bags with sample number tickets. Core samples are drilled using HQ core barrels to below the level of oxidation and then reduced to NQ core barrels for the remainder of the bore hole. Samples are transported to the SGS Côte d’Ivoire facility in Yamoussoukro by Kobo personnel where the entire sample was prepared for analysis (prep code PRP86/PRP94). Sample splits of 50 grams were then analysed for gold using 50g Fire Assay as per SGS Geochem Method FAA505. QA/QC procedures for the drill program include insertion of a certificated standards every 20 samples, a blank every 20 samples and a duplicate sample every 20 samples. All QAQC control samples returned values within acceptable limits.

Review of Technical Information

The scientific and technical information in this press release has been reviewed and approved by Paul Sarjeant, P.Geo., who is a Qualified Person as defined in National Instrument 43-101. Mr. Sarjeant is the President and Chief Operating Officer and Director of Kobo.

About Kobo Resources Inc.

Kobo Resources is a growth-focused gold exploration company with a compelling gold discovery in Côte d’Ivoire, one of West Africa’s most prolific gold districts, hosting several multi-million-ounce gold mines. The Company’s 100%-owned Kossou Gold Project is located approximately 20 km northwest of the capital city of Yamoussoukro and is directly adjacent to one of the region’s largest gold mines with established processing facilities.

With over 47,500 metres of diamond drilling, 5,887 metres of reverse circulation (RC) drilling, and 7,200+ metres of trenching completed since 2023, Kobo has made significant progress in defining the scale and prospectivity of its Kossou’s Gold Project. Exploration has focused on multiple high-priority targets within a 9+ km strike length of highly prospective gold-in-soil geochemical anomalies, with drilling confirming extensive mineralisation at the Jagger, Road Cut, and Kadie Zones. The latest phase of drilling has further refined structural controls on gold mineralisation, setting the stage for the next phase of systematic exploration and resource development.

Beyond Kossou, the Company is advancing exploration at its Kotobi Permit and is actively expanding its land position in Côte d’Ivoire with prospective ground, aligning with its strategic vision for long-term growth in-country. Kobo remains committed to identifying and developing new opportunities to enhance its exploration portfolio within highly prospective gold regions of West Africa. Kobo offers investors the exciting combination of high-quality gold prospects led by an experienced leadership team with in-country experience.

Kobo’s common shares trade on the TSX Venture Exchange under the symbol “KRI” and on the Frankfurt Stock Exchange under the symbol “Q1Z”. For more information, please visit www.koboresources.com.

For further information, please contact:

Edward Gosselin
Chief Executive Officer and Director
1-418-609-3587
ir@kobores.com

X: @KoboResources | LinkedIn: Kobo Resources Inc.

NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary Statement on Forward-looking Information:

This press release may contain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements, including statements related to the exploration program of the Company. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable as at the date of this press release, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inherent risks involved in the exploration and development of mineral properties; unanticipated costs and expenses; the delay or failure to receive board, shareholder or regulatory approvals; and other risk factors listed from time to time in documents filed by the Company with Canadian securities regulators on SEDAR+ at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, Kobo assumes no obligation or liability to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/656354d2-4c8d-43b1-aa3f-72bc61cef38e

https://www.globenewswire.com/NewsRoom/AttachmentNg/cfaab198-2080-4411-b411-4dc6d0de89e9

https://www.globenewswire.com/NewsRoom/AttachmentNg/77220253-abaa-4841-907e-38238831fb43

https://www.globenewswire.com/NewsRoom/AttachmentNg/5cfccaeb-142d-4d89-9a72-154bd5ec6947

Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment

Median interval between end of initial treatment course and first retreatment infusion was 16.6 months

No new safety signals reported; safety profile consistent with previously reported data

Topline data from Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis expected in 1Q27

FREDERICK, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced additional positive retreatment data of its lead investigational asset, Descartes-08, in patients with generalized myasthenia gravis (MG), being presented today during the Myasthenia Gravis Foundation of America (MGFA) Scientific Session of the 2026 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting being held in Orlando, Florida.

Descartes-08 is Cartesian’s autologous anti-B cell maturation antigen (BCMA) chimeric antigen receptor T-cell therapy (CAR-T) in clinical development for MG and myositis. Dr. James F. Howard Jr., M.D., a distinguished neurologist at the University of North Carolina School of Medicine and investigator in the Phase 2b trial, will present the case series of five retreated patients who experienced clinically meaningful improvements in MG severity scores following a recurrence of MG symptoms at least 12 months after the initial course of Descartes-08 treatment.

“There remains a significant unmet need for patients suffering from MG today where current treatment options require patients to utilize chronic immunosuppressants to manage the disease,” said James F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and Allied Health at the University of North Carolina School of Medicine. “Descartes-08 is designed to target BCMA+ immune cells in MG to potentially provide patients with sustained symptom improvement reflected in clinically significant MG-ADL reductions with the added ability to be re-dosed if symptoms recur. For patients who have already cycled through multiple therapies, the option to retreat a CAR-T cell therapy, in an outpatient setting and without lymphodepleting chemotherapy, represents an exciting potential advancement in the field of MG.”

12-Month Retreatment Results

The data presented today at AANEM analyzed the efficacy, safety, and durability of Descartes-08 retreatment in five patients with MG who previously received a full treatment course in the Phase 2 portion of the trial and experienced recurrence of symptoms (Myasthenia Gravis Activities of Daily Living [MG-ADL] ≥6) following 12-month follow-up. Similar to the initial course of treatment, retreatment consisted of six once-weekly Descartes-08 infusions. Clinical outcomes were assessed by mean change in Myasthenia Gravis Composite (MGC) and MG-ADL scores from baseline through Month 12. Safety and tolerability were also assessed across treatment courses.​ Patients had a mean disease duration of 13 years with extensive treatment histories.

Efficacy

• Patients retreated (n=5) at a median of 16.6 months following completion of initial treatment course experienced greater improvement in MG symptoms compared to initial course of treatment; mean decrease in MG-ADL scores were sustained through 12 months following retreatment
  • Retreated patients observed an average MG-ADL reduction of 6.6 (±4.2) points from baseline at Month 12.
  • Retreated patients observed an average MGC reduction of 15 (±6.2) points from baseline at Month 12.
  • All retreated patients experienced a clinically meaningful reduction across MGC (≥3-point reduction) and MG-ADL scores (≥2-point reduction), and four patients maintained the clinically meaningful MG-ADL reduction through Month 12 following retreatment.

Safety

• Consistent safety data observed to date supports potential retreatment of Descartes-08 following recurrence of MG symptoms, as clinical benefit was observed with no new safety concerns
  • Descartes-08 was observed to be generally well-tolerated through Month 12 following retreatment, and adverse events were transient and mild. No serious adverse events were reported during retreatment. Notably, there were no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, or hypogammaglobulinemia.

“Descartes-08’s clinical data generated to date has demonstrated the potential for meaningful clinical responses that persist through 12 months following the completion of an initial course of treatment, with the ability to be re-dosed if needed. Unlike currently approved therapies that generally require cyclical dosing to maintain effect, Descartes-08 is being developed with the goal of providing sustained clinical benefit following a finite course of treatment.,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “We believe the combination of sustained symptom improvement, the ability to retreat if symptoms return, and the quality-of-life benefits of outpatient administration without lymphodepleting chemotherapy sets Descartes-08 apart and has the potential to meaningfully change the way MG is treated. These data strengthen our conviction in Descartes-08 as we approach topline results from our Phase 3 AURORA trial, expected in the first quarter of 2027.”

Descartes-08 was previously granted Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of MG. Cartesian received written agreement from the FDA under the Special Protocol Assessment (SPA) process indicating the overall design of the planned Phase 3 AURORA trial of Descartes-08 is acceptable to support a future biologics license application (BLA) in MG, subject to the ultimate outcome of the trial. Cartesian remains on track to readout topline data from its Phase 3 AURORA trial of Descartes-08 in MG in the first quarter of 2027, with a BLA filing expected in mid-2027.

About Descartes-08

Descartes-08, Cartesian’s lead cell therapy candidate, is an investigational, autologous CAR-T product targeting BCMA in clinical development for generalized MG and myositis, specifically dermatomyositis and antisynthetase syndrome. In contrast to conventional DNA-based CAR T-cell therapies, Cartesian’s CAR-T administration is designed to not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation by the U.S. Food and Drug Administration for the treatment of MG, and Rare Pediatric Disease Designation for the treatment of juvenile dermatomyositis.

About Cartesian Therapeutics

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.

Forward Looking Statements

Any statements in this press release about the future expectations, plans and prospects of the Company, including without limitation, the ability of the Company’s product candidates to be administered in an outpatient setting or without the need for preconditioning lymphodepleting chemotherapy, the potential of Descartes-08, or any of the Company’s other product candidates to treat MG, juvenile MG, myositis, juvenile dermatomyositis, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, including the ongoing Phase 3 AURORA trial of Descartes-08 in MG, the ongoing Phase 2 TRITON trial of Descartes-08 in myositis, and the ongoing Phase 1/2 HELIOS pediatric trial of Descartes-08 in autoimmune diseases, including juvenile dermatomyositis, the anticipated timing or the outcome of the FDA’s review of the Company’s regulatory filings, including the number of trials that may be necessary in order to obtain marketing approval, the potential for in-vivo delivery of the Company’s product candidates, the Company’s ability to conduct its clinical trials and preclinical studies, the timing or making of any regulatory filings, the anticipated timing or outcome of selection of developmental product candidates, the ability of the Company to enter into and maintain potential collaborations or partnerships, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, and enrollment in the Company’s clinical trials and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company’s technology, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, political uncertainty, the Company’s reliance on third parties to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company’s common stock, risks related to geopolitical conflicts, pandemics, and macroeconomic impacts, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release, except as required by law.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com

Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies

VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or the “Company“), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the “Board“).

Ms. Pump is a seasoned finance executive with more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres.

“We are pleased to welcome Melanie to Optimi’s Board,” said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. “Her extensive financial leadership experience across technology-driven and emerging growth companies, together with her public company board experience, will add valuable perspective as Optimi continues to execute on its strategic priorities and advance its position in the regulated psychedelic pharmaceutical market.”

Ms. Pump also currently serves on the Board of Directors of Mobio Technologies Inc. (TSXV: MBO) and previously served as a director of BTCS Inc. Her background combines senior financial leadership with public company governance experience across a range of technology-focused and growth-oriented businesses.

“I’m pleased to join Optimi’s Board at an important stage in the Company’s development,” said Melanie Pump. “Optimi has built a strong foundation in regulated psychedelic drug manufacturing and is advancing meaningful opportunities for growth. I look forward to working with Dane, the Board and the broader leadership team, and to contributing my experience in finance, governance and emerging growth companies as Optimi continues to execute on its strategic priorities.”

The Company also announces that Leah Hodges has resigned as Corporate Secretary of the Company. Dane Stevens, the Company’s Chief Executive Officer has been appointed to fill the role. The Company thanks Mrs. Hodges for her service.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
CORE IR
ir@optimi.net

Forward-Looking Statements

This press release may contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Future results may differ materially from those expressed or implied in any forward-looking statement. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. In this news release, forward-looking statements and forward-looking information relate to, among other things, information regarding: the Company’s execution of its strategic priorities, position in the regulated psychedelic pharmaceutical market, opportunities for growth, and the contribution of Ms. Pump’s experience going forward. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. These risk factors include, among other things, market acceptance of the Company’s products, as well as those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.com and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.com. Forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategy

PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it has submitted an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration (“FDA”) for Teverelix®, its investigational, next generation, long-acting GnRH antagonist, in advanced prostate cancer (“APC”) patients at increased cardiovascular (“CV”) risk.

The submission is designed to establish a defined, capital-efficient and partner-ready registrational pathway for Teverelix without Medicus independently funding an additional clinical development study in the APC program at this time. Importantly, the proposed design is stage-gated: it begins with approximately 80 randomized patients, incorporating and replacing the previously FDA-cleared stand-alone 40-patient open-label Phase 2b dose-optimization study. Once predefined continuation criteria have been satisfied, the program would then proceed to add approximately 528 patients, for approximately 608 patients in total, with eligible patients from the initial stage contributing to the final registration analyses.

If the FDA agrees with the proposed approach, Medicus believes the optimized design could reduce the overall planned clinical development program from approximately 1,500 patients to approximately 600 patients while providing a single pathway encompassing dose optimization, androgen suppression and prospective evaluation of cardiovascular differentiation in APC patients at increased cardiovascular risk, without an upfront commitment to enroll the full study population.

Following FDA feedback, and subject to the nature of that feedback, Medicus’ intent is to seek to out-license or otherwise strategically partner the Teverelix APC program rather than independently fund execution of the proposed registrational study.

There can be no assurance that the FDA will agree with the proposed protocol, that the optimized development pathway will ultimately support registration, or that Medicus will successfully enter into a licensing or other strategic transaction involving Teverelix.

Management Commentary

“Our objective with this submission is not to commit Medicus capital to another APC clinical study—it is to define the most efficient registrational pathway possible and make Teverelix ready for a strategic partner,” stated Dr. Raza Bokhari, Executive Chairman and CEO of Medicus. “The FDA previously cleared a 40-patient open-label dose-optimization study. Rather than independently funding that study, we have now proposed an approximately 600-patient seamless registration-intent program that incorporates a more rigorous 80-patient randomized dose-optimization stage and could reduce the overall development population from ~ 1,500 patients to ~ 600 and is more likely to be partner-ready.”

Designed to Reach Partner Readiness Without Additional Medicus R&D Spend

The submission represents a further implementation of the Company’s capital-efficient portfolio strategy announced on September 8, 2026, under which Medicus is concentrating capital and organizational resources on programs where focused clinical development may offer the most compelling risk-adjusted opportunity.

Medicus’ objective with the current FDA submission is to complete the regulatory optimization of the Teverelix APC development pathway before committing additional internal capital to clinical execution.

If the FDA provides constructive feedback on the proposed approach, Medicus intends to use the resulting regulatory-defined development pathway as the basis for strategic partnering discussions and seek a pharmaceutical partner to fund and execute subsequent APC clinical development and commercialization

From FDA-Cleared Dose Optimization to a Seamless Registration-Intent Program

On February 10, 2026, Medicus announced that FDA had provided “Study May Proceed” clearance for a 40-patient open-label Phase 2b dose-optimization study of Teverelix in men with advanced prostate cancer appropriate for androgen deprivation therapy. That study was designed to confirm the Teverelix dosing regimen and sustained testosterone suppression.

In addition to focusing its efforts towards GMP grade manufacturing, quality-release, and other clinical study readiness steps, which are anticipated to be completed before the end of this year, the Company continued to optimize the APC development strategy. The newly submitted protocol proposes an approximately 80-patient randomized dose-optimization stage as the first part of an approximately 608-patient seamless Phase 2b/3 registration-intent study. Subject to predefined criteria, the study would then continue with approximately 528 additional patients, with eligible patients from the initial stage contributing to the final registration analyses.

The proposed design is intended to avoid conducting a stand-alone dose-optimization study followed by a separate, substantially larger Phase 3 program. Compared with a previously discussed development approach involving approximately 1,500 patients, the seamless strategy could reduce total planned enrollment by approximately 60% while reducing duplication, time and capital requirements associated with sequential studies.

Cardiovascular-Focused Registrational Strategy

The optimized strategy incorporates emerging randomized clinical evidence published in JAMA Cardiology in 2026 showing that differences in coronary plaque progression between GnRH treatment pathways can be objectively measured over 12 months using non-invasive coronary CT angiography (“CCTA”). CCTA can be incorporated into a multicenter study using standardized scans at baseline and Month 12 with blinded central quantitative analysis.

The proposed protocol combines established testosterone-suppression requirements with a 12-month coronary non-calcified plaque endpoint, while allowing longer-term cardiovascular event follow-up to continue in the same patients. The development strategy is designed to evaluate whether Teverelix can achieve effective androgen deprivation while demonstrating cardiovascular differentiation in advanced prostate cancer patients already at increased CV risk.

If the FDA agrees that this approach could support registration, Medicus believes the proposed design could provide a substantially shorter and more capital-efficient development pathway than the previously contemplated sequential program. Any development timeline remains subject to FDA feedback, successful study execution, enrollment, clinical results and regulatory review.

About Teverelix®

Teverelix® is an investigational next-generation, long-acting GnRH antagonist formulated as a microcrystalline suspension. Unlike GnRH agonists, which induce an initial testosterone surge, Teverelix provides immediate receptor antagonism, enabling rapid suppression of luteinizing hormone, follicle-stimulating hormone and downstream sex hormones without flare. Medicus is evaluating Teverelix across hormone-dependent indications and is pursuing a capital-efficient development strategy intended to advance programs through regulatory and clinical value-creating milestones while evaluating strategic partnership opportunities.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations 
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.

The Company’s current therapeutic assets are:

CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.

SkinJect®, an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.

Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.

Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking statements” or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements”). “Forward-looking statements” are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the development of SkinJect® and the potential benefits thereof for those suffering with Gorlin Syndrome, the development of Teverelix® and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix® for AURr, cardiovascular high-risk advanced prostate cancer, women’s health indications like endometriosis, the FDA’s feedback regarding the Company’s Phase 2b/3 registration-intent protocol for Teverelix® in APC, the proposed design of the Phase 2b/3 registration-intent program, the potential to reduce the overall planned APC clinical development program from approximately 1,500 patients to approximately 600 patients, the establishment of a defined, capital-efficient and partner-ready registrational pathway for Teverelix® without Medicus independently funding an additional APC clinical development study, Medicus’ intent and ability to out-license or otherwise strategically partner the Teverelix® APC program, the anticipated completion of GMP-grade manufacturing, quality-release and other clinical study readiness steps before the end of 2026, whether the proposed cardiovascular-focused registrational strategy, including the 12-month non-calcified coronary plaque endpoint assessed using non-invasive coronary CCTA and the evaluation of Teverelix® effects on APC patients at increased cardiovascular risk, could support registration, the Company’s capital-efficient portfolio strategy and the anticipated benefits thereof, the Company’s co-development with Pfizer with respect to CD228V and the anticipated benefits thereof, the Company’s plans and expectations relating to the development, manufacture and commercialization of CD228V across human therapeutic indications, including the Company’s intention to focus initial development on melanoma with potential subsequent development in squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer, the timing, design, conduct and results of any future clinical study of CD228V, and the potential market opportunities related to CD228V, SkinJect® and Teverelix® and the Company’s other therapeutic assets. Forward-looking statements are often, but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2025, and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. (“StorageVault”) (SVI-TSX) is pleased to announced its intention to repay in full on October 1, 2026, being the first business day following the maturity date of September 30, 2026 (the “Maturity Date”) all of its then-outstanding 5.50% senior unsecured hybrid debentures due on the Maturity Date (the “Debentures”) in accordance with the provisions of the trust indenture (the “Indenture”) dated July 19, 2021, between the Corporation and TSX Trust Company (the “Trustee”).

The cash payment for the repayment in full of the Debentures will be 100% of the aggregate outstanding principal amount, together with accrued and unpaid interest up to, but excluding, the Maturity Date (the “Maturity Date Payment”). In accordance with the Indenture, StorageVault intends to satisfy its obligation to pay the Maturity Date Payment to the Trustee in cash. Interest upon the entire aggregate principal amount of the Debentures will cease to be payable from and after the Maturity Date. The Corporation intends to use cash on hand to repay the Debentures.

The Debentures are listed on the Toronto Stock Exchange (“TSX”) under the symbol “SVI.DB.B” and will be delisted from the facilities of the TSX on September 30, 2026 in connection with their repayment at maturity. Beneficial owners of the Debentures are encouraged to contact their investment dealer if they have any questions.

About StorageVault Canada Inc.
StorageVault currently owns and operates 275 storage locations across Canada. StorageVault owns 243 of these locations plus over 5,000 portable storage units representing over 13.8 million rentable square feet on 802 acres of land. StorageVault also provides last mile storage and logistics’ solutions and professional records management services, such as document and media storage, imaging and shredding services.

For further information, contact Mr. Steven Scott or Mr. Iqbal Khan:

Tel: 1-877-622-0205

ir@storagevaultcanada.com

Follow us:
Instagram: @accessstorageca @depotiumminientrepot @sentinelstorageca @cubeitportablestorage
Facebook: /AccessStorageCA /Depotium /SentinelStorageCanada /Cubeit /FlexSpaceLogistics

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information regarding: the Corporation’s intention to repay the Debentures, including the amount of the Maturity Date Payment. There can be no assurance that such forward-looking information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects StorageVault’s current beliefs, estimates, forecasts and projections and is based on information currently available to StorageVault and on assumptions StorageVault believes are reasonable. These assumptions include, but are not limited to, assumptions regarding: the Trustee processing the Maturity Date Payment; and the delisting of the Debentures occurring on September 30, 2026. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of StorageVault to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board of directors, third party or regulatory approvals; the actual results of StorageVault’s future operations; competition; changes in legislation, including environmental legislation, affecting StorageVault; the timing and availability of external financing on acceptable terms; conclusions of economic evaluations and appraisals; lack of qualified, skilled labour or loss of key individuals; and the impact that the imposition of trade tariffs, particularly from the United States, may have on the global economy, and the economy in Canada in particular‎. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in StorageVault’s disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although StorageVault has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of StorageVault as of the date of this news release and, accordingly, is subject to change after such date. However, StorageVault expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy

Data Further Support Company’s Plans to Advance Iopofosine I 131 in Phase 3 Confirmatory Trial and Submit for U.S. Accelerated Market Approval in 1H27

FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that a subset analysis of data from the company’s Phase 2 CLOVER WaM clinical trial that support the potential of iopofosine I 131 as a potential treatment option for Waldenström Macroglobulinemia (WM) patients who are refractory or resistant to BTK inhibitor therapy will be highlighted in a presentation at the upcoming International Workshop for Waldenström Macroglobulinemia (IWWM) taking place October 14 – 16, 2026 in Palm Springs, California.

“We are pleased to present these data from the CLOVER-WaM study at IWWM and share additional evidence supporting the potential of iopofosine I 131 to address a significant unmet need for patients with WM. This analysis evaluated patients who received iopofosine I 131 immediately following BTK inhibitor therapy after at least two prior lines of treatment, representing a particularly challenging, heavily pretreated population,” said Jarrod Longcor, chief operating officer at Cellectar Biosciences. “We remain on-target to dose patients in the confirmatory Phase 3 clinical trial in early 2027 and to file our New Drug Application for accelerated approval in the first half of 2027. Given iopofosine I 131 has Breakthrough Therapy Designation, we expect a six-month review with a potential approval by the end of 2027.”

Details of the upcoming poster presentation are as follows:

Title:	“Iopofosine I 131 After BTK Inhibitors in Waldenström Macroglobulinemia: CLOVER-WaM Subgroup Efficacy and Safety”
Session #:	14
Date/Time:	October 15, 2026, 4:00 PM
Location:	Sierra-Ventura Hall
Presenter:	Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences

About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.

Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b study for TNBC, which will determine the recommended dose for the subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth.

In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit https://www.cellectar.com/ or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.

Forward Looking Statements Disclaimer
This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the FDA and EMA regulatory pathways, ability to execute strategic alternatives, identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2025, and our Form 10-Q for the quarterly period ending June 30, 2026. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

INVESTORS:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com

MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, announces the completion of the previously announced transaction under which PyroGenesis Inc. (“PyroGenesis”) converted its 10% gross sales royalty into a 50% ownership interest in HPQ Silica Polvere Inc. (“HSPI”).

The transaction was completed after HPQ and PyroGenesis executed a definitive shareholders’ agreement and completed the related share transfer. As a result, HPQ and PyroGenesis now each hold a 50% ownership interest in HSPI, the rights holder of the proprietary Fumed Silica Reactor (“FSR”) technology.

In a separate release issued today, PyroGenesis provides an update on preliminary discussions concerning potential applications of the FSR. HPQ summarizes those discussions below because they concern HSPI, which the companies now own equally. No definitive commercial agreement has been entered into in respect of any of these opportunities.

50/50 Ownership Establishes Common Commercialization Platform

Before completing the transaction, HPQ wholly owned HSPI and funded FSR development through the pilot phase. PyroGenesis developed and built the FSR and remains HSPI’s exclusive equipment supplier for its commercialization.

The FSR converts quartz (SiO₂) directly into fumed silica in a single step, eliminating the need for chlorosilanes and the associated hydrogen chloride (HCl) generation found in conventional production methods.

As HPQ disclosed on July 8, 2026, the FSR pilot program achieved its two principal objectives: demonstrating the production of commercial-grade fumed silica directly from quartz and generating the engineering and operating data required to support the design, costing and economic evaluation of future commercial production facilities. The pilot program produced commercial-grade “150” fumed silica, with independent testing validating its commercial performance.

Following the pilot program, PyroGenesis completed an extensive engineering review of the operating data generated during pilot production. The results strengthened confidence in the projected operating parameters and commercial-scale economics of the FSR technology and provided HSPI with an improved engineering basis for evaluating potential commercial deployments.

Update on Preliminary Commercial Discussions

These discussions are preliminary. No definitive agreement has been entered into for any of the opportunities described below, and there is no assurance that any will proceed.

As described by PyroGenesis, discussions concerning the FSR involve four potential opportunities:

Global Fumed Silica Manufacturer: Discussions have resumed with a global manufacturer of fumed silica that previously signed a letter of intent outlining collaboration during the FSR pilot phase. After completing the pilot objectives, the parties are evaluating potential frameworks for the next phase of collaboration, including opportunities to support commercial deployment of the FSR. An additional meeting is scheduled for the week of September 28 to discuss the potential go-forward framework.

Proposed 1,000 Tonne-Per-Year Joint Venture: Discussions have resumed regarding the previously announced potential joint venture for a 1,000 tonne-per-year fumed silica production facility. According to PyroGenesis, its team recently met with the potential partner at one of its U.S. facilities to discuss proposed changes. Both sides received the proposed changes favorably, and negotiations have resumed. Any joint venture remains subject to definitive agreements.

Potential Asian Customer and North American Production: Discussions continue with a potential Asian customer interested in establishing production capacity in North America. Discussions have included potential large-scale bulk supply and/or local FSR production facilities. According to PyroGenesis, the potential customer previously indicated that demand could require several 10,000 tonne-per-year FSR systems and has recently requested a meeting at PyroGenesis’ headquarters to accelerate discussions.

Potential Middle East Production Facility: PyroGenesis reports that discussions remain planned with an existing PyroGenesis customer with significant operations in the Middle East regarding a potential local fumed silica production facility. Previous discussions contemplated a potential facility with production capacity of approximately 10,000 tonnes per year.

There can be no assurance that any discussion will result in a definitive agreement or commercial project.

Management Commentary

“Completing this transaction brings HPQ and PyroGenesis together as equal shareholders in HSPI,” said Bernard Tourillon, Chairman, President and CEO of HPQ Silicon and President and CEO of HSPI. “HPQ funded development of the FSR through the pilot phase, while PyroGenesis developed and built the reactor. We now have a common ownership structure for decisions concerning the technology.”

“PyroGenesis has also provided an update on several preliminary commercial discussions involving the FSR. These discussions are at different stages, and none has resulted in a definitive commercial agreement. We will report on any material developments as they occur.”

About HPQ Silica Polvere Inc. (“HSPI”) and the Fumed Silica Reactor (“FSR”)

HPQ Silica Polvere Inc. (“HSPI”) is jointly owned by HPQ Silicon Inc. and PyroGenesis Inc., with each holding a 50% ownership interest. HSPI holds the rights to the proprietary Fumed Silica Reactor (“FSR”) technology, while PyroGenesis is the exclusive supplier of equipment for its commercialization.

The FSR is a plasma-based technology that uses quartz (SiO₂) as feedstock to directly produce commercial-grade fumed silica in a single process. Unlike conventional production methods requiring chlorosilanes, the FSR eliminates the need for chlorosilane feedstock and the associated generation of hydrogen chloride (HCl).

Expected benefits include lower capital and operating costs, reduced CO₂ emissions and energy footprint, simplified logistics, and reduced requirements for hazardous chemical handling and storage.

About HPQ Silicon

HPQ Silicon Inc. is a Quebec-based TSX Venture Exchange industrial issuer (TSX-V: HPQ) focused on innovation in advanced materials and critical process development. In partnership with its research and development partner Novacium—of which HPQ is a shareholder—the Company is advancing next-generation silicon-based anode materials (Gen3 and Gen4) for batteries, commercializing its ENDURA+ lithium-ion cells, and developing breakthrough clean-hydrogen and waste-to-energy technologies, for which HPQ holds exclusive North American rights.

HPQ is also pursuing proprietary technologies to become a low-cost, zero-CO₂ producer of fumed silica and high-purity silicon, with technical support from PyroGenesis Inc. Together, these initiatives position HPQ to capture growth opportunities in the energy storage, clean hydrogen, and advanced materials markets essential to achieving global net-zero goals. For more information, please visit HPQ Silicon web site.

About PyroGenesis Inc.

PyroGenesis leverages 35 years of plasma technology leadership to deliver advanced engineering solutions to energy, propulsion, destruction, process heating, emissions, and materials development challenges across heavy industry and defense. Its customers include global leaders in aluminum, aerospace, steel, iron ore, utilities, environmental services, military, and government. From its Montreal headquarters and local manufacturing facilities, PyroGenesis’ engineers, scientists, and technicians drive innovation and commercialization of energy transition and ultra-high temperature technology. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified, with ISO certification maintained since 1997. PyroGenesis’ shares trade on the TSX (PYR), OTCQX (PYRGF), and Frankfurt (8PY1) stock exchanges. www.pyrogenesis.com

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements regarding HPQ Silicon’s Fumed Silica Reactor project. Such statements reflect management’s expectations on future performance, pilot plant testing, commercialization, financing, and strategic milestones. They involve assumptions about technology, market conditions, financing, permits, supply chains, and economic factors. However, risks—including delays, financing challenges, regulatory changes, competition, commodity prices, geopolitical factors, and market demand—may cause actual results to differ materially.

Readers are cautioned that forward-looking information is uncertain and not guarantees of future performance. Additional risk factors are detailed in HPQ’s Annual Information Form on SEDAR+. A more detailed cautionary note regarding forward-looking information related to HPQ Fumed Silica is available for download [here]. Further information regarding the Company is available in the SEDAR+ database (www.sedarplus.ca), and on the Company’s website at: http://www.hpqsilicon.com/

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders. 

Source: HPQ Silicon Inc.

For further information contact:

Bernard J. Tourillon, BAA – MBA, Chairman, President, and CEO
Tel +1 (514) 846-3271 Email: Info@hpqsilicon.com

High-grade Zones of 13.39 g/t AuEq over 1.18 m and 17.28 g/t AuEq 0.50 m

VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to announce the final drill results from the Camp Creek high-sulphidation target at its wholly owned Thorn Project in NW British Columbia, Canada. The fourteen holes reported herein, together with hole THN26-372 (see news release of June 30, 2026), complete the fifteen-hole 2026 campaign at that target. The Company has commenced work on a Mineral Resource Estimate with APEX Geoscience Ltd. covering both the high-sulphidation zone and the deeper Camp Creek porphyry, with results expected in the first quarter of 2027. The Company completed 6592.30 m of drilling in 25 holes at Thorn in 2026, and drilling is now complete for the season. Assays are pending from the Catalyst and Sentinel porphyries and the Trapper Gold Target.

Highlights

• Drilling returned wide gold-silver-copper intervals and high-grade intervals in the near surface high-sulphidation zone at Camp Creek, which remains open along strike and down-dip.
   
• Hole THN26-371 returned 58.00 m of 0.40 g/t gold and 6.40 g/t silver (0.50 g/t AuEq) from 48.00 m depth
   
  • Including 3.00 m of 2.10 g/t gold and 14.70 g/t silver (2.34 g/t AuEq) from 87.50 m depth
     
  • and 3.00 m of 2.34 g/t gold and 21.70 g/t silver (2.68 g/t AuEq) from 103.00 m depth
     
• Hole THN26-385 returned 17.58 m of 0.62 g/t gold, 44.00 g/t silver and 0.24% copper (1.47 g/t AuEq) from 135.52 m depth
   
  • Including 1.18 m of 5.78 g/t gold and 405.00 g/t silver, 1.97% copper (13.39 g/t AuEq) from 150.59 m depth
     
• Hole THN26-383 returned 22.94 m of 0.37 g/t gold and 9.80 g/t silver (0.57 g/t AuEq) from 100.06 m depth, and two high-grade zones deeper in the hole
   
  • 0.50 m of 0.54 g/t gold and 326.00 g/t silver, 0.49% copper (5.65 g/t AuEq) from 203.04 m depth
     
  • and 0.50 m of 1,100 g/t silver, 1.35% copper and 0.31 g/t gold (17.28 g/t AuEq) from 218.00 m depth

Gary R. Thompson, Chairman and CEO, stated, “These results show that what was originally interpreted as a single Glenfiddich vein is in fact a broader zone of multiple composite veins that continues to depth. Nearly all holes reported here returned wide gold-silver-copper intervals, with high-grade zones. The Glenfiddich Zone was extended to 580 m along strike, 350 m down-dip, and it remains open. We look forward to updating the 2014 MRE on these near surface mineralized zones including Oban, Talisker, Glenfiddich and Northside.”

Figure 1. Photographs of cut HQ core from holes THN26-371 at 105.15 m and THN26-379 at 58.5 m depth, showing brecciated semi-massive quartz-pyrite-sulphosalt-sphalerite-galena mineralization.

Figure 2. Target locations on the Thorn Property, NW British Columbia, with copper values in soil and rock samples across the property.

Table 1. Selected assay intervals in Camp Creek holes presented herein.

Hole ID	From (m)	To (m)	Interval (m)	Au (g/t)	Ag (g/t)	Cu (%)	AuEq g/t)
THN26-371	48.00	106.00	58.00	0.40	6.4	0.01	0.50
including	87.50	90.50	3.00	2.10	14.7	0.03	2.34
including	103.00	106.00	3.00	2.34	21.7	0.03	2.68
THN26-373	92.20	93.50	1.30	1.68	136.2	0.54	4.13
THN26-373	127.55	168.00	40.45	0.32	8.0	0.03	0.46
including	142.22	142.87	0.65	3.86	15.1	0.01	4.09
THN26-374	68.00	74.00	6.00	0.44	76.3	0.30	1.81
including	68.00	69.00	1.00	0.53	57.6	0.30	1.63
including	72.00	74.00	2.00	0.84	162.0	0.60	3.71
THN26-374	155.00	170.50	15.50	0.39	14.2	0.12	0.71
including	155.00	156.00	1.00	1.12	132.0	1.34	4.25
THN26-375	145.85	189.11	43.26	0.43	9.3	0.05	0.61
including	171.62	172.67	1.05	1.58	13.0	0.05	1.81
including	176.00	178.00	2.00	1.62	8.7	0.06	1.80
including	182.00	183.00	1.00	1.07	8.0	0.09	1.27
THN26-376	157.00	216.00	59.00	0.33	8.8	0.04	0.49
including	201.00	202.64	1.64	1.85	14.9	0.12	2.18
THN26-377	153.50	155.00	1.50	1.29	0.1	0.00	1.29
THN26-378	48.25	72.00	23.75	0.46	9.0	0.07	0.65
including	64.50	66.00	1.50	2.59	29.0	0.10	3.10
including	70.45	72.00	1.55	1.78	53.9	0.50	3.02
THN26-379	40.00	66.00	26.00	0.40	9.8	0.03	0.57
including	58.40	59.00	0.60	5.34	143.0	0.28	7.64
including	60.84	62.20	1.36	1.47	35.3	0.19	2.16
THN26-380	54.00	56.77	2.77	0.80	14.3	0.03	1.04
including	54.00	55.00	1.00	1.26	26.0	0.05	1.68
THN26-381	50.50	76.00	25.50	0.45	11.0	0.02	0.63
including	55.65	56.20	0.55	1.17	39.4	0.05	1.78
including	67.40	69.00	1.60	1.42	19.8	0.10	1.79
including	70.00	71.00	1.00	1.01	11.0	0.04	1.20
THN26-382	145.00	185.00	40.00	0.32	8.5	0.08	0.52
including	154.00	156.44	2.44	1.58	48.7	0.40	2.65
THN26-383	100.06	123.00	22.94	0.37	9.8	0.07	0.57
including	100.06	102.00	1.94	1.47	30.4	0.22	2.11
including	103.00	104.00	1.00	1.24	9.0	0.07	1.43
including	108.03	109.04	1.01	1.09	53.0	0.70	2.50
THN26-383	203.04	203.54	0.50	0.54	326.0	0.49	5.65
THN26-383	218.00	218.50	0.50	0.31	1,100.0	1.35	17.28
THN26-384	No significant intercepts
THN26-385	135.52	153.10	17.58	0.62	44.0	0.24	1.47
including	139.19	141.00	1.81	1.08	117.0	0.80	3.50
including	150.59	151.77	1.18	5.78	405.0	1.97	13.39

Reported intervals are drill core lengths; true widths of the mineralized intervals have not yet been determined. Composite intervals were selected using gold as the lead element at a 0.30 g/t Au cut-off, built from contiguous samples with unlimited internal dilution. A composite is reported only where it contains at least one sample exceeding 1.00 g/t Au, 50 g/t Ag or 0.50% Cu; holes with no such sample are reported as having no significant intercepts. Intervals labelled “including” are contiguous runs of samples exceeding one or more of those thresholds. All reported grades are length-weighted averages. 

Gold equivalent (AuEq) is calculated as: AuEq (g/t) = Au (g/t) + (Cu% × 0.9306) + (Ag (g/t) × 0.0143). Factors are derived from trailing 12-month average metal prices of US$4.75/lb copper, US$3,500/oz gold and US$50/oz silver, using conversions of 22.0462 lb per tonne per 1% Cu and 31.10348 g per troy ounce. AuEq is presented on a gross metal value basis and assumes 85% metallurgical recovery of the three elements.

Discussion

The objective of the 2026 Camp Creek high-sulphidation drilling campaign was to expand the northeast-trending mineralization identified in previous drilling at the Glenfiddich Zone and support the Company’s maiden Mineral Resource Estimate for the target (for historical estimates, see news releases of October 29, 2014 and July 9, 2021).

Holes THN26-371, THN26-372 and THN26-378 through THN26-381 were drilled to infill the known Glenfiddich Zone and test its extension at surface. The holes traced the near-surface vein zone across the drilled area and returned consistent gold and silver widths. Results for hole THN26-372 were reported previously and are not repeated in Table 1; that hole returned 14.75 m of 1.25% copper, 1.71 g/t gold and 149.00 g/t silver from 84.25 m depth, including 1.50 m of 8.33% copper, 11.30 g/t gold and 971.00 g/t silver (see news release of June 30, 2026). Hole THN26-371 returned 58.00 m of 0.40 g/t gold and 6.40 g/t silver from 48.00 m, and hole THN26-379 returned 26.00 m of 0.40 g/t gold and 9.80 g/t silver from 40.00 m, including 0.60 m of 5.34 g/t gold and 143.00 g/t silver.

Holes THN26-373 through THN26-377 and THN26-382 tested the down-dip continuation of the Glenfiddich Zone, and all six holes intersected mineralization. What was previously interpreted as a single vein, or at most a pair of veins, is now understood to be a series of stacked, sub-parallel veins that continue at depth (Figures 3 and 4). Hole THN26-375 returned 43.26 m of 0.43 g/t gold and 9.30 g/t silver from 145.85 m, and hole THN26-376 returned 59.00 m of 0.33 g/t gold and 8.80 g/t silver from 157.00 m. These widths reflect multiple veins and intervening altered wall rock rather than a single structure and demonstrate vertical continuity of the Glenfiddich vein system.

Holes THN26-383, THN26-384 and THN26-385 tested the continuation of the Glenfiddich structures west of the Le Jeune Creek fault zone. Two of the three holes extended the zone across that structure and returned the highest silver grades of the campaign. Hole THN26-385 returned 17.58 m of 0.62 g/t gold, 44.00 g/t silver and 0.24% copper from 135.52 m, including 1.18 m of 5.78 g/t gold, 405.00 g/t silver and 1.97% copper, and hole THN26-383 returned 0.50 m of 1,100.00 g/t silver and 1.35% copper from 218.00 m. The Company interprets the Glenfiddich high-sulphidation veins as the shallow expression of the Camp Creek porphyry system at depth, so their continuation beyond the fault suggests the porphyry may also extend to the west. Future deep drilling will test this concept.

The results reported herein complete the Company’s assay reporting for the Camp Creek high-sulphidation target and will be incorporated into the Mineral Resource Estimate now underway with APEX Geoscience Ltd. The Company expects to report estimates for both the Camp Creek high-sulphidation zone and the deeper Camp Creek porphyry in the first quarter of 2027.

Figure 3. HQ core box photograph of hole THN26-375 from 177.55 to 187.21 m, showing sheeted, sub-parallel galena-sphalerite-sulphosalt veins and brecciated intervals with the same mineral assemblage.

Figure 4. All drill results in the Glenfiddich area only.

Table 2. Collar information for holes reported herein, Glenfiddich Zone, Thorn Project.

Hole ID	Easting (m)	Northing (m)	Elevation (m)	Azimuth	Dip	Depth (m)
LM-26-371	607600	5270850	220.9	90	-60	249.00
LM-26-374	607280	5271020	215.7	130	-58	219.00
LM-26-375	607500	5270780	217.3	90	-55	249.00
LM-26-378	607180	5271020	207.1	90	-60	201.00
LM-26-379	607500	5270780	217.3	85	-60	252.00
LM-26-381	607500	5270780	217.3	95	-60	249.00
LM-26-382	607180	5271020	207.1	160	-55	202.00
LM-26-383	607500	5270780	217.3	95	-50	246.00
LM-26-384	607180	5271020	207.1	270	-55	201.00
LM-26-385	607510	5270760	216.9	90	-55	300.00
LM-26-386	607180	5271020	207.1	20	-60	201.00
LM-26-387	607510	5270760	216.9	90	-60	300.00
LM-26-388	607180	5271020	207.1	20	-50	219.00
LM-26-389	607510	5270760	216.9	95	-55	261.00
LM-26-390	607330	5271060	217.0	90	-50	210.00
LM-26-391	607510	5270760	216.9	250	-60	204.00
LM-26-392	607330	5271060	217.0	225	-50	210.00
LM-26-393	607510	5270760	216.9	85	-57	198.00
LM-26-394	607324	5270862	215.0	90	-58	201.00
LM-26-395	607531	5270764	217.1	80	-55	300.00
LM-26-396	607324	5270862	213.2	90	-60	216.00
LM-26-398	607077	5270856	209.8	275	-55	201.00
LM-26-399	607540	5270746	216.8	80	-50	300.00
LM-26-400	607077	5270856	209.8	275	-60	123.00
LM-26-401	607077	5270856	209.8	290	-45	180.00
LM-26-402	607077	5270856	209.8	275	-45	219.00
LM-26-403	607541	5270746	216.9	80	-55	300.00
LM-26-404	607077	5270856	209.8	290	-55	116.00
LM-26-405	607210	5270820	212.0	300	-55	213.00
LM-26-406	607077	5270856	209.8	290	-60	165.00
LM-26-407	607541	5270746	216.9	80	-45	321.00
LM-26-408	607210	5270820	212.0	300	-50	198.00
LM-26-432	607433	5270886	218.8	230	-66	199.00

Quality Assurance & Quality Control

Quality assurance and quality control protocols for drill core sampling were developed by Brixton. Core samples were mostly taken at 1.5 m intervals. High-grade intervals were taken at 0.50 to 1.50 m intervals. Blank, duplicate (lab pulp) and certified reference materials were inserted at a combined rate of up to 15%. Core samples were cut in half, bagged, zip-tied and sent directly to the ALS Minerals preparation facility in Whitehorse, Yukon or Langley, British Columbia, depending on available lab capacity. ALS Minerals Laboratories is registered to ISO 9001:2008 and ISO 17025 accreditations for laboratory procedures. Samples were analyzed at ALS Laboratory Facilities in North Vancouver, British Columbia, for gold by fire assay with an atomic absorption finish, whereas Ag, Pb, Cu, Zn, and 48 additional elements were analyzed using four-acid digestion with an ICP-MS finish. Over-limit gold samples were analyzed using fire assay and gravimetric finish. The standards, certified reference materials, were acquired from CDN Resource Laboratories Ltd., of Langley, British Columbia, and the standards inserted varied depending on the type and abundance of mineralization visually observed in the primary sample. Blank material used consisted of non-mineralized siliceous landscaping rock. A copy of the QAQC protocols is available on the Company’s website.

Qualified Person (QP)

Ms. Madeline Berry, P.Geo., is a Project Geologist for the Company and is a Qualified Person as defined by National Instrument 43-101. Ms. Berry has verified the referenced data disclosed in this press release and has approved the technical information presented herein.

About Brixton Metals Corporation

Brixton Metals is a Canadian exploration company focused on the advancement of its mining projects. Brixton wholly owns four exploration projects: Brixton’s flagship Thorn copper-gold-silver-molybdenum Project, the Langis and Hudson Bay silver Projects in Ontario, the Hog Heaven copper-silver-gold Project in NW Montana, USA, which is optioned to Ivanhoe Electric Inc., and the Atlin Goldfields Project located in northwest BC, which is optioned to Eldorado Gold Corporation. Brixton Metals Corporation shares trade on the TSX-V under the ticker symbol BBB, and on the OTCQX under the ticker symbol BBBXF. For more information about Brixton, please visit our website at www.brixtonmetals.com.

On Behalf of the Board of Directors

Mr. Gary R. Thompson, Chairman and CEO
info@brixtonmetals.com

For Investor Relations inquiries please contact: Mr. Michael Rapsch, Vice President Investor Relations. email: michael.rapsch@brixtonmetals.com or call Tel: 604-630-9707

Follow us on:
LinkedIn | Twitter/X | Facebook | Instagram

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, including statements that address potential quantity and/or grade of minerals, potential size and expansion of a mineralized zone, proposed timing of exploration and development plans, or other similar expressions. All statements, other than statements of historical fact included herein including, without limitation, statements regarding the use of proceeds. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. 

Links:

https://brixtonmetals.com/wp-content/uploads/2026/09/Figure-1-NR-29Sept2026.png

https://brixtonmetals.com/wp-content/uploads/2026/09/Figure-2-NR-29Sept2026.png

https://brixtonmetals.com/wp-content/uploads/2026/09/Figure-3-NR-29Sept2026w-scaled.png

https://brixtonmetals.com/wp-content/uploads/2026/09/Figure-4-NR-29Sept2026-scaled.png

More than US$800,000 in additional recurring cash costs eliminated since July 1, 2026, through tech delivery, AI supported workflows and operating discipline

Highlights

• Over US$2.51 million in total annualized cash operating cost reductions now implemented
• Over US$800,000 of additional annualized recurring cash costs eliminated since July 1, 2026
• Cumulative annualized cash operating cost reductions increased by 47.2% in less than three months
• New reductions comprise approximately US$445,000 in staff costs, US$181,000 in taxes and benefits, US$116,000 in premises costs and US$64,000 in technology subscriptions and cloud storage
• Technology delivery and AI supported workflows are enabling MMA.INC to streamline operations and operate with a leaner recurring cost base
• All savings result from completed actions embedded in the Company’s operating model
• Lower recurring cash outflows are expected to strengthen operating leverage, extend runway and support the Company’s path toward positive adjusted EBITDA

New York, NY, Sept. 29, 2026 (GLOBE NEWSWIRE) — Mixed Martial Arts Group Limited (NYSE American: MMA) (“MMA” or the “Company”), doing business as MMA.INC, today announced more than US$800,000 in additional annualized cash operating cost reductions, increasing total annualized cash operating cost reductions to over US$2.51 million.

The new reductions were implemented between July 1 and September 28, 2026 and represent a 47.2% increase from approximately US$1.71 million of annualized cash operating cost reductions reported as of June 30, 2026.

The additional savings comprise approximately:

• US$445,000 in staff costs;
• US$181,000 in associated taxes and benefits;
• US$116,000 in premises costs; and
• US$64,000 in technology subscriptions and cloud storage.

Each announced reduction arises from a completed action and represents recurring cash expenditure that management believes is no longer required by the business.

Technology and AI Support Operating Leverage

MMA.INC’s technology delivery program and expanded use of AI supported workflows are enabling the Company to simplify processes, automate manual activity, consolidate infrastructure and support a leaner operating structure.

These actions delivered over US$625,000 in additional workforce related annualized cash cost reductions and over US$180,000 in technology and operating infrastructure annualized cash cost reductions during the period.

The Company believes its technology investment is strengthening MMA.INC’s product platform while reducing the recurring cash cost required to operate the business.

Nick Langton, Founder and Chief Executive Officer of MMA.INC, said:

“Since June 30, we have increased MMA.INC’s annualized cash operating cost reductions from approximately US$1.71 million to approximately US$2.51 million. That 47.2% increase reflects the pace and discipline with which we are reshaping the business.

“Technology delivery, automation and AI supported workflows are translating directly into lower recurring cash costs. We are simplifying how MMA.INC operates, removing expenditure the business no longer requires and building a more scalable operating model.

“These are completed actions, not future targets. We have now removed over US$2.51 million of annualized recurring cash expenditure from the business, strengthening operating leverage, extending runway and supporting our path toward profitability.”

MMA.INC intends to continue pursuing disciplined efficiencies while protecting its core revenue-generating capabilities and strategic priorities. Positive adjusted EBITDA is an operating objective, not a forecast, and the Company is not providing a quantitative target or fixed timetable.

Basis of Annualized Cash Operating Cost Reduction Measure

The annualized cash operating cost reduction of approximately US$2.51 million represents management’s estimate, as of September 28, 2026, of recurring annual cash expenditure eliminated through actions completed between January 1, 2025 and September 28, 2026. The figure is intended to describe annualized recurring cash cost reductions from completed actions and should not be read as a forecast of future profitability, cash flow or financial performance.

The measure was calculated by annualizing each identified cash cost at the rate applying immediately before its elimination. It includes payroll, taxes and benefits, premises, hosting, insurance, technology subscriptions, cloud storage and costs eliminated through the deprecation of selected Hype functionality.

The measure excludes share-based payments, depreciation, amortization and other non-cash expenses.

About Mixed Martial Arts Group Limited

Mixed Martial Arts Group Limited (NYSE American: MMA), doing business as MMA.INC, is building the participation and technology platform for the global martial arts and combat sports industry, connecting practitioners, gyms, coaches, content, commerce and payments.

As of July 2026, MMA.INC’s platform assets included 5 million+ social media followers, 680,000 user profiles, 107,694 registered student profiles, 27,651 monthly active users and 15,326 published gym profiles, including 996 verified and 389 paying academies. The platform also recorded approximately 80,000 monthly check-ins and an annualized payments run rate of approximately US$21 million based on May 2026 processing volumes.

• A Connected Participation Platform: MMA.INC brings together gym software, payments, training, community, content and commerce through assets including BJJLink, TrainAlta, Hype and MixedMartialArts.com.
• A Growing Participation Network: Over the prior 18 months, registered student profiles increased approximately 101%, monthly active users approximately 89% and paying academies approximately 260%.
• Built to Aggregate the Sector: MMA.INC’s strategy is to connect the fragmented martial arts participation economy through a unified digital identity and ecosystem designed to deepen engagement and expand monetization across software, payments, programs, memberships, partnerships and commerce.

For more information, visit www.mma.inc

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Sections 27A of the Securities Act of 1933, as amended, and 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than statements of historical fact and may be identified by words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “target,” “objective,” “may,” “will,” “could,” “should,” “continue,” “potential” and similar expressions. Forward-looking statements in this release include, without limitation, statements regarding the expected amount, timing and durability of the Company’s annualized cash operating cost reductions; the Company’s ability to maintain a lower recurring cost base; the anticipated benefits of technology delivery, automation and AI-supported workflows; the expected effects of the cost reductions on operating leverage, cash usage, cash runway, margins, adjusted EBITDA, profitability and financial condition; the scalability of the Company’s operating model; and the Company’s intention to identify and implement further efficiencies without compromising its revenue-generating capabilities, product delivery or strategic priorities. These forward-looking statements are based on management’s current expectations, estimates, assumptions and information available as of the date of this release. Actual results could differ materially due to risks and uncertainties including, among others: the risk that estimated or annualized savings are not realized, maintained or reflected in future operating results at the amounts or within the periods anticipated; the possibility that savings are offset by restructuring or transition costs, wage or supplier inflation, replacement expenditure, additional hiring, technology investment or other operating requirements; the accuracy and completeness of the data and assumptions used to calculate and annualize the cost reductions; the risk that workforce reductions, organizational changes or infrastructure consolidation disrupt operations, internal controls, product development, customer service or revenue growth; the Company’s ability to successfully implement and maintain technology, automation and AI-supported processes; cybersecurity, data protection, privacy, reliability and other risks arising from increased reliance on technology and AI; the Company’s ability to retain key personnel and maintain relationships with customers, gyms, academies, partners and suppliers; the Company’s ability to grow revenue, improve margins and manage its liquidity and capital requirements; general economic, market and regulatory conditions; and the Company’s ability to access additional capital when required. Additional risks and uncertainties include those described under “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and in subsequent reports on Form 6-K filed with or furnished to the U.S. Securities and Exchange Commission. The annualized cost-reduction figures presented in this release are management estimates based on the recurring cash costs applying immediately before the relevant costs were eliminated. They are not forecasts of future profitability, cash flow or financial performance. Cost reductions alone may not result in positive adjusted EBITDA or profitability, and there can be no assurance that the Company will achieve those objectives within any particular period or at all. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update or revise them as a result of new information, future events or otherwise, except as required by applicable law.

Media Contacts

Mixed Martial Arts Group Limited
E: andrew@mma.inc